Matches in Nanopublications for { ?s ?p "[Use of tyrosine kinase inhibitors for AML therapy is hindered by the acquisition of mutations in the kinase catalytic domain, and in the case of BCR-ABL, these mutations confer resistance to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- assertion description "[Use of tyrosine kinase inhibitors for AML therapy is hindered by the acquisition of mutations in the kinase catalytic domain, and in the case of BCR-ABL, these mutations confer resistance to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP473099.RAi2jQWpFZvJqwUuO2XlQzvHxFuLpTECNc3wKi79NvN2E130_assertion description "[Use of tyrosine kinase inhibitors for AML therapy is hindered by the acquisition of mutations in the kinase catalytic domain, and in the case of BCR-ABL, these mutations confer resistance to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP473099.RAi2jQWpFZvJqwUuO2XlQzvHxFuLpTECNc3wKi79NvN2E130_provenance.